STOP T1D

01/16/2026

On behalf of the Barbara Davis Center for Diabetes and the STOP T1D Program

We invite you to the FOURTH session of “Office Hours” with Ask the Experts

This 1-Hour Zoom-session will be held on
Wednesday January 21st, 2026
at NOON (MST) / 2 PM (EST)

Hosted by the Ask the Experts Team

Please come prepared to discuss early cases you may have questions about. Attendees will also have the opportunity to ask general questions related to early screening and follow-up monitoring.

We look forward to your attendance and participation!

REGISTER to Join: https://www.asktheexperts.org/office-hours-jan21

Please SAVE-THESE-DATES of our upcoming “Office Hours”
February 18, 2026
March 18, 2026
Participants may earn 1 CME credit (for each of the 6 planned monthly "Office Hours" Zoom calls, for a total of up to 6 CME credits)

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Ask the Experts and this Office Hours program is supported by The Leona M. and Harry B. Helmsley Charitable Trust.

Registration Form for our monthly "Office Hours" Zoom call for HCPs — to discuss early T1D questions and cases.

01/16/2026

We agree! General population screenings for as young as age one is an important health risk assessment that could save lives and improve outcomes.

To learn more about no cost screenings for type 1 diabetes (and disease), please visit our colleagues offering these screenings at ASKhealth.org

"If population screening for is pursued, models that integrate primary care will be needed. Screening for type 1 diabetes through primary care well-child visits could enable high adoption if implementation strategies adequately address described barriers and promote facilitators.'

Population Screening for Type 1 Diabetes in Pediatrics via Well-Child Visits: Barriers and Facilitators to Implementation https://diabetesjournals.org/spectrum/article/doi/10.2337/ds25-0036/163858/Population-Screening-for-Type-1-Diabetes-in

A research program offering FREE SCREENINGS to Colorado kids (ages 1-17), and their parents, to detect Type 1 Diabetes and Celiac (at Barbara Davis Center for Diabetes, CU Anschutz Medical Campus)

01/14/2026

Young adults, emerging from care originating from their childhood families/guardians, needs to be adapted as they take on those health responsibilities for themselves once becoming independent.

"The findings of this study highlight the importance of adapting adult care systems and providers' approaches to meet the self-identified needs of young adults to improve engagement with care and potentially avoid adverse outcomes in this high-risk people population."

Diabetic Medicine | Diabetes UK Journal | Wiley Online Library https://onlinelibrary.wiley.com/doi/10.1111/dme.70214

01/13/2026

Cerebral microbleeds (CMBs) "were related to a subtle, yet systematic impairment in cognition, whereas mild WMHs were not. The results provide insight into the development of early cSVD-related cognitive changes already in midlife and suggest an increased risk of cognitive decline in ."

Read the research report: "Cerebral microbleeds are associated with deficits in cognitive processing speed and executive functions in middle-aged adults with type 1 diabetes" > https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)01095-2/fulltext

Individuals with type 1 diabetes (T1D) have an elevated risk of microvascular complications, including diabetic kidney disease, retinopathy, and cerebral small vessel disease (cSVD) [1,2]. CSVD affects brain’s microvessels and leads to diverse pathology seen on brain imaging, typically in the elde...

01/12/2026

New research report out of Denmark: In men with type 1 diabetes (T1D), an intravenous infusion of glucose‑dependent insulinotropic polypeptide (GIP) did not prevent hypoglycaemia when prandial insulin was given in excess and participants performed postmeal physical activity, but it modestly reduced the peak glucose levels observed after meals compared with the GIP receptor antagonist GIP(3-30)NH2."

"'Our findings suggest that supraphysiological levels of GIP do not protect against hypoglycaemia in T1 diabetes, consistent with the similar glucagon levels observed during GIP, the GIPR [GIP receptor] antagonist GIP(3-30)NH2, and placebo infusions.'"

Read: GIP Reduces Meal Peaks but Not Hypoglycaemia in T1D > https://www.medscape.com/viewarticle/gip-reduces-meal-peaks-not-hypoglycaemia-t1d-2026a10000bx

In men with type 1 diabetes, intravenous glucose-dependent insulinotropic polypeptide can reduce postprandial plasma glucose levels but does not protect against hypoglycaemia.

01/09/2026

New in research on the impacts of children who are overweight...

"According to our results, children who are overweight are exposed to a more severe clinical presentation of T1DM. Weight loss, as a typical symptom of newly diagnosed T1DM, might mislead caregivers, considering it a positive factor. In addition, in the case of overweight and obesity, many associate it with type 2 diabetes mellitus (T2DM) and indicate lifestyle intervention. Therefore, the diagnosis of T1DM might be delayed. In our research, children with overweight were diagnosed in a worse condition (lower pH and HCO3-) than obese children. "

Frontiers | Overweight worsens the metabolic presentation of type 1 diabetes mellitus in children https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1740046/full

IntroductionThe prevalence of both obesity and type 1 diabetes mellitus (T1DM) has increased globally over the last decades. Overweight and obesity affect in...

01/08/2026

New Therapy First to Target Type 1 Diabetes Disease Process https://news.cuanschutz.edu/news-stories/new-therapy-first-to-target-type-1-diabetes-disease-process

"Tzield (teplizumab-mzwv) is the first and only therapy approved by the FDA to delay of the clinical onset (stage-3) of type 1 diabetes. The drug was brought to market by Provention Bio (now part of Sanofi), a pharmaceutical company focused on treatments for autoimmune diseases. Tzield was extensively studied through multiple clinical trials before receiving approval from the FDA in November 2022. In clinical trials, Tzield was shown to delay the median onset of clinical type 1 diabetes by 25 months, providing patients additional time during which they do not need to inject insulin and providing them more time to prepare for the challenges associated with living with type 1 diabetes."

"Receiving Tzield requires meeting certain clinical indications which will be assessed by your doctor. The infusion regimen is completed over 14 days, consecutively, and each infusion visit takes approximately 3-4 hours."

A patient became the first person in Colorado to receive a newly-approved drug that is the first treatment ever aimed at delaying onset of type 1 diabetes.

01/07/2026

Get to know the outstanding physicians and specialists working with us at the Barbara Davis Center for Diabetes!

Meet Dr. Greg Forlenza, Pediatric Endocrinologist at the Barbara Davis Center!

His journey into diabetes care began at diabetes camp during medical school, where working alongside children and leaders in the field sparked a lifelong passion for type 1 diabetes.

With a unique interest in technology, Dr. Forlenza has helped lead the development of automated insulin delivery systems—once thought impossible and now standard of care for kids with diabetes.

His work is driven by one goal: using innovation to improve quality of life for children and their families, one breakthrough at a time. 💙

01/05/2026

It's a New Year! What a great time to learn more about type 1 diabetes, including T1D patient screenings, diagnoses, and monitoring while earning 2026 credits!

STOP T1D offers a type 1 diabetes education program for health care providers developed by the researchers and physicians at the Barbara Davis Center for Diabetes (BarbaraDavisCenter.org).

STOPT1Dprogram.org provides , , and professionals free Continuing Medical Education credits through online learning that you can access any time it's convenient for you.

Take the program modules at your own pace from your computer or mobile device. Most people complete them in a couple of hours. The course covers:

• Screening methods and confirmation
• Target populations
• Communication of results
• Patient monitoring
• Available intervention and clinical trial opportunities
• Implementation of screening and monitoring into health systems

Earn Continuing Medical Education credits while advancing your knowledge and awareness on the importance of T1D screenings.

visit STOPT1Dprogram.org/for-hcp to review the program and take the course for FREE.

12/08/2025

Earn credits from your at STOPT1Dprogram.org!

Check out the newest features making it easier to learn about type 1 diabetes from your mobile device and computer. STOP T1D's modules cover:

• Screening methods and confirmation
• Target populations
• Communication of results
• Patient monitoring
• Available intervention and clinical trial opportunities
• Implementation of screening and monitoring into health systems

LATEST UPGRADES
✓ Learning modules optimized for mobile
✓ ChatBot ready to answer your questions
✓ Updated and expanded content
✓ Play-on-demand audio narration for charts, figures, tables, and images
✓ Early T1D Registry information
✓ Additional resources within modules especially for HCPs

STOP T1D offers , , and professionals FREE Continuing Medical Education credits through online learning that you can access any time it's convenient for you. The program was developed by top research physicians at the Barbara Davis Center for Diabetes (BarbaraDavisCenter.org).

visit https://www.stopt1dprogram.org/for-hcp to review the free program and register to receive credits (stopt1dprogram .org/for-hcp).

12/04/2025

Using a US commercial insurance claims database, scientific researchers studied the prevalence of cardiovascular disease (CVD) in U.S. "among commercially insured adults [20 years and older] with in the USA from 2017 to 2021."

In summary:

"Cardiovascular disease (CVD), the most common cause of death among individuals with type 1 diabetes (T1D), is associated with hyperglycemia, hypertension, and hyperlipidemia. In the USA, few studies report the prevalence of CVD in people with T1D, particularly among younger adults, as well as the trends and relationship with hypoglycemia."

"From 2017–2021, the prevalence of CVD among commercially insured adults with T1D remained stable at around 20%. CVD prevalence was higher among individuals with a history of severe hypoglycemia and hyperglycemic emergencies along with other comorbidities."

"This study documents the persistent burden of CVD among adults with T1D, highlights the importance of managing comorbidities to reduce risk, and shows the need to further explore the association between comorbidity control and CVD."

Read the full report: "Trends in cardiovascular disease prevalence among adults with type 1 diabetes in the USA: analysis of commercial claims data, 2017–2021" https://drc.bmj.com/content/13/6/e005121

12/03/2025

New in research on how kids managing falter in their glycemic control after summer camp ends...

"Children and adolescents with T1D maintain adequate glycemic control during camp, but experience a transient post-camp deterioration, underscoring the need for monitoring and individualized support during the week following camp."

When the summer camp ends: Short-term, post-camp deterioration of glycemic control in youth with type 1 diabetes https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)01054-X/abstract

To investigate short-term post-camp glycemic deterioration in youth with T1D using sensor-augmented or automated insulin delivery systems and to identify contributing factors.